Metoclopramide as Treatment of Clozapine-induced Hypersalivation
Study Details
Study Description
Brief Summary
Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable adverse effect of clozapine therapy that can lead to noncompliance. Until now there is no effective enough treatment for this side effect.
Previous studies demonstrated that different medications from the substitute benzamide derivatives group: amisulpride, sulpiride (higher selective binding to the D2/D3 dopamine receptor) and moclobemide (reversible inhibitor of monoamine oxidase A, which inhibits the deamination of serotonin, norepinephrine and dopamine) may be effective as a treatment of clozapine-induced hypersalivation (CIH). Moreover, there is another substitute benzamide derivative: metoclopramide (dopamine D2 antagonist, usually used as antiemetic medication in general medicine). The investigators hypothesis assumes that anti-salivation effect characterizes the whole group of benzamide.
The aim of this study was to examine the efficacy of metoclopramide as an optional possibility for management of CIH.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable adverse effect of clozapine therapy that may persist for several years. This side effect is usually dose-related. It may occur all over the day, but it is most pronounced during night sleep, since swallowing reflex is diminished, and patients usually complain of wakening with a wet pillow (sometimes called as "wet pillow" sign).
Salivation is regulated by sympathetic (adrenergic) and parasympathetic (cholinergic) tones. The phenomenon of clozapine-induced hypersalivation (CIH) remains mysterious since the drug has potent α2 antagonistic, M4 - muscarinic agonistic, and anticholinergic (M1, M2, M3, and M5) activities and each of these has a different effect on the control of salivation. While α2 antagonistic and M4 - muscarinic agonistic effects increase salivation, the anticholinergic effect leads to diminished saliva secretion. It has been reported that CIH is observed from 10 to 80% of patients according to various sources, an average rate is 30% of clozapine-treated patients. Further to the social embarrassment related to hypersalivation, additional consequences of CIH include painful parotid gland swelling and parotid duct obstruction due to the formation of calculi.
Clozapine is a second generation neuroleptic agent whose structure consists of a dibenzodiazepine derivative with a piperazinyl side chain. It has a unique neuropharmacologic profile, which is attributed to atypical antipsychotic agents with proven efficacy in refractory schizophrenia, but its widespread use is limited by adverse effects such as agranulocytosis, seizures, sedation, weight gain, and sialorrhea. Clozapine has a weak binding affinity for dopamine D1 and D2 receptors by its slightly greater preference for D1 receptors, as noted with a D1:D2 receptor binding ratio of 1:3. Furthermore the drug has potent binding affinity for serotonin receptors 5-HT1A and 5-HT2, and also antihistaminic, anticholinergic, and alpha-adrenergic antagonistic properties.
Sialorrhea is troublesome its stigmatizing nature results for a schizophrenia patient led to massive compliance problems. For management of this distressing side effect have been recommended different pharmacological agents such as α2 - adrenoreceptor agonists, including clonidine, and lofexidine, but these treatments have unwanted side effects, no proved effectiveness. They are not been routinely used. These publications show that CIH probably might have a different neurobiological basis rather than the proposed mediation by the M4 - muscarinic receptor.
Previous studies found that substitute benzamide derivatives with higher selective binding to the D2/D3 dopamine receptors - amisulpride, sulpiride as well moclobemide (reversible inhibitor of monoamine oxidase A, which inhibits the deamination of serotonin, norepinephrine and dopamine) may be effective in treatment of CIH without additional adverse effects. Unfortunately, these medications are not effective in all patients who suffered from CIH.
Metoclopramide was first described by Dr. Louis Justin-Besançon and C. Laville in 1964. It is a dopamine D2 receptor antagonist, and a mixed 5-HT3 receptor antagonist. Moreover, it is a 5-HT4 receptor agonist.
Metoclopramide is fairly often used in general medicine as an antiemetic agent. In 1979, FDA approved it for treatment of nausea and vomiting. This drug also belongs to substitute benzamide derivatives group. It is assumed that the anti-emetic activity is caused by its D2 receptor antagonism in the chemoreceptor trigger zone in the central nervous system. Dry mouth is one of its side effects. The investigators hypothesized that antisalivation effect characterizes the whole group of benzamides, and will be demonstrated also in none psychotropic agent like metoclopramide.
The aim of our study was to examine efficacy of metoclopramide as an additional agent for management of CIH and to approve our hypothesis.
Subjects and Methods The study was conducted from January 2012 to May 2014 in two large state referral institutions: Tirat Carmel Mental Health Center and the Be'er-Sheva Mental Health Center. The investigators screened 68 patients (males and females, 19-60 years old) suffering from schizophrenia and schizoaffective disorders, treated with clozapine, and suffering from hypersalivation. Of all screened subjects, 7 patients refused to take part in the study.
Inclusion criteria were: a) males and females in age 18-60 years old; b) met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, criteria for schizophrenia or schizoaffective disorder; c) Clozapine treatment for a minimum of 2 months;
- Constant dose of clozapine and other concomitant medications during previous 2 weeks; e) At least 2 points on the Nocturnal Hypersalivation Rating Scale (NHRS);3 f) Ability and willingness to sign informed consent for participation in the study.
Study exclusion criteria included: a) the Presence of concurrent medical conditions contributing to hypersalivation (eg, idiopathic Parkinson's disease, cerebral palsy); b) Evidence of mental retardation; c) Alcohol or drug abuse. Patients who had been treated with anticholinergic agents and continued to experience CIH were allowed to participate in the study, provided they continued to suffer from CIH of at least moderate severity. Complete medical and neurological examinations, including laboratory tests, were performed. Prior to study entry, all subjects who met the inclusion criteria provided written informed consent after receiving a full explanation regarding the nature of the study and potential risks and benefits. The study was approved by both the Tirat Carmel Mental Health Center and the Be'er Sheva Mental Health Center Institutional Review Boards.
Study Design The study was conducted in two mental health centers. In order to examine our hypothesis, the investigators used an add-on design. Sixty-one patients with schizophrenia and schizoaffective disorder (males and females, 19-60 years old), according to the DSM-IV criteria, treated with clozapine and suffering from hypersalivation, enrolled into the study (30 patients in metoclopramide group and 31 in the placebo group).
Procedure and drug administration In order to find a minimal effective dose, all subjects suffering from CIH (score >2 on Nocturnal Hypersalivation Rating Scale - NHRS) in a double blind randomized mode were treated during a week with 10 mg/day of metoclopramide or placebo. The patients without improvement continuing the study with 20 mg/day of metoclopramide or placebo during the next week. Those patients, who did not respond to this dose, were continued with 30 mg/day of metoclopramide or placebo for another week.
Hypersalivation will be assessed by subjective and objective tools. Clinical global impression (CGI) patient's self-assessment will be taken as a subjective tool while NHRS and Drooling Severity Scale (DSS) as an objective one. NHRS consists of the 5-points: 0-absent; 1-minimal (signs of saliva on the pillow in the morning); 2-mild (hypersalivation wakes the patient once during the night); 3-moderate (hypersalivation wakes the patient twice during the night), and 4-severe (hypersalivation wakes the patient at least 3 times during the night). DSS also consists of the 5-points: 1- never drools, 2 -mild, only wet lips, 3-moderate, wet on lips and chin, 4-severe, clothing becomes wet and 5 - profuse, clothing, hands, tray, and objects become wet. Assessment was performed on baseline (entering into the study) and every morning during the study period and two weeks after ceasing the add-on medications.
Clinically significant improvement was defined as a reduction of at least 30% from baseline to week 2 on the NHRS and DSS.
Participants Thirty patients from Be'er Sheva Mental Health Center and 31 from Tirat Carmel Mental Health Center have participated in the study.
The study was approved by the local Institutional Ethics Review Board ("Helsinki Committee"). Only subjects who will and able to sign a written informed consent form for participation in the study, were recruited. Confidentially was ensured by means of a number coding system, and all completed research forms were stored in a secure area.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: metoclopramide 61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode |
Drug: Metoclopramide
30 mg/day during 4 weeks
Drug: placebo
|
| Experimental: metocliopramide 61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode |
Drug: Metoclopramide
30 mg/day during 4 weeks
Drug: placebo
|
Outcome Measures
Primary Outcome Measures
- Nocturnal Hypersalivation Rating Scale (NHRS) [every week, up to 4 weeks]
Secondary Outcome Measures
- Drooling Severity Scale (DSS) [every week, up to 4 weeks]
Other Outcome Measures
- The Positive and Negative Syndrome Scale (PANSS) [every week, up to 4 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18-60 years, male or female
-
DSM-IV criteria for schizophrenia
-
Clozapine treatment
-
At least score >2 on the Nocturnal Hypersalivation Rating Scale (NHRS)
Exclusion Criteria:
-
Evidence of organic brain damage, mental retardation, alcohol or drug abuse
-
Patients suffering from pheochromocytoma
-
Patients suffering from Parkinson's disease
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Be'er Sheva Mental Health Center, | Be'er Sheva | Israel | 8417000 |
Sponsors and Collaborators
- Beersheva Mental Health Center
- Tirat Carmel Mental Health Center
Investigators
- Study Director: Vladimir Lerner, MD, PhD, Ben-Gurion University of the Negev
Study Documents (Full-Text)
None provided.More Information
Publications
- VLAK-14